Project description DEENESFRITPL A device for treating complications after heart surgery Following cardiac surgery, many patients develop postoperative atrial fibrillation (POAF), a type of arrhythmia that increases the risk for stroke by nearly threefold. To avoid the use of drugs, the EU-funded DefiPace-System project will bring to the market a device that facilitates the prevention and treatment of POAF in post-operative patients. The device helps the heart restore its physiological pace through a process known as bi-atrial pacing without the need for anaesthesia. More importantly, it is hand-held, easy to use and can be employed by clinical staff in the general ward of any hospital. Show the project objective Hide the project objective Objective The incidence of cardiac surgeries is increasing world-wide in view of the demographic change. Cardiac surgery carries asignificant amount of risk as on average 60% of patients develop postoperative atrial fibrillation, by far the most frequentlyoccurring complication after cardiac surgery. Clinical investigations show a significant increase in morbidity, mortality andduration of treatment and hospital stay. The risk for stroke is increased 3-fold! From all discussions with renowned surgeonsresults the clear statement that an avoiding or reduction of medical drugs is in any circumstance a preferable and desirableambition. The DefiPace™ system is a proven and awaited method by the physicians treating post-operative patients. Ournew system is unique, as it is the only system in history and today, which allows physicians to prevent and terminate postoperativeatrial fibrillation (POAF) in all patients. It is the only system which combines standard stimulation, bi-atrial pacingas well as epicardial low-energy cardioversion in one hand-held easy-to-use device even on general ward. Target customersare all patients undergoing cardiac surgery world-wide (market volume: € 1.5 billion). Advantages: Simplicity • TMA pacing &cardioversion wires: easy to use, similar to standard pacing wires • DefiPace device: Intuitive handling for clinical staff similarto standard external pacemakers Prevention and Termination: • Bi-atrial pacing as an effective way to prevent POAF •Quick Termination of atrial fibrillation with safe, elegant low energy cardioversion • No anesthesia necessary Cost savingsfor surgical clinics • Significant cost savings: at least €1,000per day/patient Improved health • Few or no medicationrequired • All complications from atrial fibrillation can be completely avoided The DefiPace™-System is as a key product forOSYPKA and will lead to significant increase of sales and employees. We will revolutionize the pacemaker market a secondtime in our history Fields of science social sciencessociologydemographymortalitymedical and health sciencesclinical medicinesurgerymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesbasic medicineneurologystroke Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2b - SME Instrument (grant only and blended finance) Coordinator OSYPKA AG Net EU contribution € 1 969 950,50 Address Earl h wood strasse 1 79618 Rheinfelden baden Germany See on map Region Baden-Württemberg Freiburg Lörrach Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 844 264,50
